- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04390139
Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19 (COVIDMES)
A Prospective, Double-blind, Randomized, Parallel, Placebo-controlled Pilot Clinical Trial for the Evaluation of the Efficacy and Safety of Two Doses of WJ-MSC in Patients With Acute Respiratory Distress Syndrome Secondary to Infection by COVID-19
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a prospective, double-blind, randomized, parallel, placebo-controlled pilot clinical trial to assess the efficacy and safety of two infusions of Wharton Jelly mesenchymal stromal cells (WJ-MSC) in patients with moderate acute respiratory distress syndrome (ARDS) secondary to SARS-CoV-2 infection. The study will enroll 30 patients who after signing the informed consent will be checked for inclusion and exclusion criteria. Patients will then be randomized (1:1) to one of the 2 treatment arms: Treatment A WJ-MSC/WJ-MSC; Treatment B Placebo/ Placebo. The 2 infusions will be administered endovenously on day 1 (D1) and on D3. Thereafter, patients will be followed-up on days 3, 5, 7, 14, 21, and 28 Once the study is completed, controls will be established at 3 months, 6 months and 12 months as long-term follow-up.
The study treatments (A or B) will be added on top of the Standard of Care treatment prescribed by the attending physician. Each dose of MSC-WJ will consist of the intravenous administration of 1E6cells/Kg.
Recruitment will be competitive for the centers participating in the study. A Data Safety and Monitoring Board (DSMB) will be established to review safety and efficacy along the trial.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain, 08003
- Hospital del Mar
-
Barcelona, Spain, 08036
- Hospital Clinic de Barcelona
-
Barcelona, Spain, 08035
- Hospital Vall d'Hebron
-
-
Barcelona
-
Hospitalet de Llobregat, Barcelona, Spain, 08907
- Hospital de Bellvitge
-
Terrassa, Barcelona, Spain, 08221
- Mutua de Terrassa
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Positive PCR fpr SARS-CoV-2
- Intensive Care Unit admission for less than 3 days
- Moderate acute respiratory distress (Berlin criteria definition with 100 mmHg < PaO2/FiO2 ≤ 200 mmHg)
- Male or female, aged 18 to 70 years old
- Signed informed consent by the patient or by a legal representative (in this case, can be obtained by phone, although it must be confirmed in writing later, accepted by email)
Exclusion Criteria:
- Expected survival less than 3 days
- Treatment with immunosuppressive drugs (tocilizumab, sarilumab) with corticosteroids being allowed
- Neoplastic disease either active or without complete remission
- Immunosuppressed patients (except treatment with corticosteroids for respiratory distress)
- Pregnant or lactating women
- Participation in another clinical trial with an experimental drug in the last 30 days
- Other pathologies that, in medical judgment, contraindicate participation in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment A
Wharton-Jelly mesenchymal stromal cells on D1 and D3
|
Administration on top of the standard administered treatment
Other Names:
|
Placebo Comparator: Treatment B
Placebo on D1 and D3
|
Administration on top of the standard administered treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All-cause mortality at day 28
Time Frame: Day 28
|
Number of patients who died, by treatment group
|
Day 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of WJ-MSC
Time Frame: Day 28
|
Number of patients with treatment-emergent adverse events, by treatment group
|
Day 28
|
Need for treatment with rescue medication
Time Frame: Day 28
|
Number of patients who, after the start of treatment, required rescue medication, by treatment group
|
Day 28
|
Need and duration of mechanical ventilation
Time Frame: Day 28
|
Number of days that the patient requires invasive mechanical ventilation from the start of treatment to day +28, by treatment group
|
Day 28
|
Ventilator free days
Time Frame: Day 28
|
Days after treatment in which the patient remains alive and free of invasive mechanical ventilation, per treatment group.
|
Day 28
|
Evolution of PaO2 / FiO2 ratio
Time Frame: Day 28
|
Variation of the oxygenation index (PaO2 / FiO2) with respect to the baseline value, by treatment group.
|
Day 28
|
Evolution of the SOFA index
Time Frame: Day 28
|
Variation of the score of the Sequential Organ Failure Assessment (SOFA) Index with respect to the baseline value, by treatment group.
|
Day 28
|
Evolution of the APACHE II score
Time Frame: Day 28
|
Variation of Acute Physiology and Chronic Health disease Classification System II (APACHE II) score, by treatment group.
|
Day 28
|
Duration of hospitalization
Time Frame: Day 28
|
Days of stay in the ICU from the day of admission until discharge to day 28, or date of death if earlier, by treatment group.
|
Day 28
|
Evolution of markers of immune response (leucocyte count, neutrophils)
Time Frame: Day 28
|
Variation in the count and percentage of leukocytes and neutrophils, by treatment group.
|
Day 28
|
Feasibility of WJ-MSC administration
Time Frame: Day 28
|
Feasibility will be evaluated by the time elapsed from the request of the treatment by the hospital center until the delivery date
|
Day 28
|
Feasibility of WJ-MSC administration
Time Frame: Day 28
|
Feasibility will be evaluated by the number of patients treated within 2 days of the request for treatment.
|
Day 28
|
Evolution of disease biomarker: polymerase chain reaction (RT-PCR)
Time Frame: Day 28
|
Variation in the values of the biomarker, by treatment group.
|
Day 28
|
Evolution of disease biomarker: lactate dehydrogenase (LDH)
Time Frame: Day 28
|
Variation in the values of the biomarker, by treatment group.
|
Day 28
|
Evolution of disease biomarker: D-dimer
Time Frame: Day 28
|
Variation in the values of the biomarker, by treatment group.
|
Day 28
|
Evolution of disease biomarker: Ferritin
Time Frame: Day 28
|
Variation in the values of the biomarker, by treatment group.
|
Day 28
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Analysis of subpopulations of lymphocytes and immunoglobulins
Time Frame: Day 28
|
Blood sample analysis
|
Day 28
|
Evaluation of the in vitro response of the receptor lymphocytes
Time Frame: Day 28
|
In vitro response will be assessed using commercial viral antigens (Miltenyi Biotech)
|
Day 28
|
Study of reactivity against SARS-CoV-2 peptides
Time Frame: Day 28
|
Reactivity will be assessed using ELISPOT
|
Day 28
|
Immunophenotypic study of memory cells in response to SARS-CoV-2 peptides
Time Frame: Day 28
|
Blood sample analysis
|
Day 28
|
Genetic variability of patient's genotype in response to treatment
Time Frame: Day 28
|
Blood sample analysis for the patient's genomic sequencing
|
Day 28
|
Genetic variability of the SARS-CoV-2 genotype in response to treatment
Time Frame: Day 28
|
Genomic sequencing of the SARS-CoV-2 in a nasopharyngeal sample
|
Day 28
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Antoni Torres, MD, PhD, Hospital Clinic of Barcelona
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Respiration Disorders
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Disease
- Infant, Newborn, Diseases
- Lung Injury
- Infant, Premature, Diseases
- COVID-19
- Syndrome
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Acute Lung Injury
Other Study ID Numbers
- BST-COVID-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on XCEL-UMC-BETA
-
Banc de Sang i TeixitsSyntax for Science, S.L; Hospital de Neurorehabilitació Institut Guttmann; Recerca...CompletedSpinal Cord Injury, ChronicSpain
-
Banc de Sang i TeixitsComplexo Hospitalario Universitario de A Coruña; Institut Guttmann; Academic...CompletedSpinal Cord Injury CervicalSpain
-
Banc de Sang i TeixitsFundacion Clinic per a la Recerca BiomédicaWithdrawnFemoral Neck Fracture
-
Banc de Sang i TeixitsMinisterio de Sanidad, Servicios Sociales e Igualdad; Hospital Universitari...Completed
-
Banc de Sang i TeixitsEuropean Regional Development Fund; Ministerio de Sanidad, Servicios Sociales... and other collaboratorsCompleted
-
Banc de Sang i TeixitsTFS Trial Form Support; Ministerio de Sanidad, Servicios Sociales e Igualdad; Ministerio de Ciencia e Innovación, SpainCompletedLumbar Spondylolisthesis Involving L4-L5, and/or | Degenerative Discopathy Involving L4-L5Spain
-
Banc de Sang i TeixitsCentro Medico Teknon; Institut de Terapia Regenerativa Tissular; Cetir Sant Jordi...CompletedJoint Diseases | Rheumatic Diseases | Osteoarthritis, Knee | Knee Injuries | Cartilage DiseasesSpain
-
Banc de Sang i TeixitsHospital ASEPEYO Sant CugatCompletedAtrophic Nonunion of FractureSpain
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedChronic Obstructive Pulmonary DiseaseUnited States